News
SPRO
1.230
-1.60%
-0.020
Weekly Report: what happened at SPRO last week (0914-0918)?
Weekly Report · 5d ago
Meta Platforms To $650? Here Are 10 Top Analyst Forecasts For Monday
Benzinga · 09/14 13:01
Spero Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 09/14 10:53
Spero Therapeutics Price Target Raised to $6.00/Share From $5.00 by HC Wainwright & Co.
Dow Jones · 09/14 10:53
HC Wainwright & Co. Maintains Buy on Spero Therapeutics, Raises Price Target to $6
Benzinga · 09/14 10:42
Spero Therapeutics price target raised to $6 from $5 at H.C. Wainwright
TipRanks · 09/14 10:10
Weekly Report: what happened at SPRO last week (0907-0911)?
Weekly Report · 09/14 09:45
Weekly Report: what happened at SPRO last week (0831-0904)?
Weekly Report · 09/07 09:41
Weekly Report: what happened at SPRO last week (0824-0828)?
Weekly Report · 08/31 09:45
Spero Therapeutics Launches New Jefferies ATM Equity Program
TipRanks · 08/28 21:47
Spero Therapeutics files $300M mixed securities shelf
TipRanks · 08/28 21:10
Spero Therapeutics Files Prospectus To Offer Up To $300M In Securities
Benzinga · 08/28 21:08
Weekly Report: what happened at SPRO last week (0817-0821)?
Weekly Report · 08/24 09:46
Spero Therapeutics (SPRO) Q2 2026 Earnings Call Transcript
NASDAQ · 08/19 21:28
Weekly Report: what happened at SPRO last week (0810-0814)?
Weekly Report · 08/17 09:46
Spero Therapeutics GAAP EPS of -$0.16
Seeking Alpha · 08/12 20:14
Press Release: Spero Therapeutics Announces Second Quarter 2026 Operating Results and Provides Business Update
Dow Jones · 08/12 20:01
*Spero Therapeutics 2Q Loss $9.55M >SPRO
Dow Jones · 08/12 20:01
Press Release: Spero Therapeutics Announces -2-
Dow Jones · 08/12 20:01
*Spero Therapeutics 2Q Loss/Shr 16c >SPRO
Dow Jones · 08/12 20:01
More
Webull provides a variety of real-time SPRO stock news. You can receive the latest news about Spero Therapeuti through multiple platforms. This information may help you make smarter investment decisions.
About SPRO
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying and developing novel treatments for rare diseases and diseases caused by multi-drug resistant (MDR) bacterial infections with unmet need. Its product candidate SPR720 is an investigational, chemically stable phosphate ester prodrug that is converted in vivo to SPR719 for the treatment of nontuberculous mycobacterial (NTM) pulmonary disease. Its clinical stage product candidate, tebipenem HBr is an investigational oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections (cUTIs) including acute pyelonephritis (AP) to help patients potentially reduce duration of in-patient therapy.